Advances in Biologics for Metabolic Bone Disease
WebcastFaculty
OVERVIEW
Advances in Biologics for Metabolic Bone Disease is organized by Cleveland Clinic Center for Continuing Education and would be held during May 25, 2017 - May 25, 2019.
The target audience for this medical event for rheumatologists, allergists / immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders. This CME Conference has been approved with a maximum of 0.50 AMA PRA Category 1 Credits.
Description :
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.
This webcast reviews recent basic laboratory breakthroughs and advances in terms of their potential clinical implications and provides in-depth analyses of approved agents, new agents, predicting toxicity, clinical controversies, and new indications for metabolic bone disease.
Learning Objectives :
• Describe the mechanism of action of denosumab and the RANK ligand pathway.
• Describe the mechanism of action of romosozumab and the Wnt signaling pathway.
Additional details will be posted as soon as they are available.
The target audience for this medical event for rheumatologists, allergists / immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders. This CME Conference has been approved with a maximum of 0.50 AMA PRA Category 1 Credits.
Description :
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.
This webcast reviews recent basic laboratory breakthroughs and advances in terms of their potential clinical implications and provides in-depth analyses of approved agents, new agents, predicting toxicity, clinical controversies, and new indications for metabolic bone disease.
Learning Objectives :
• Describe the mechanism of action of denosumab and the RANK ligand pathway.
• Describe the mechanism of action of romosozumab and the Wnt signaling pathway.
Additional details will be posted as soon as they are available.
FACULTY
SPECIALITIES
OrthopedicsOsteopathic MedicineRELATED ONLINE COURSES
Quick Links